Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 61 (3), 333-335

Commentary: Treatment Failure and Success: A Commentary on Defining and Treating Pediatric Treatment-Resistant Depression - Reflections on Dwyer Et Al. (2020)

Affiliations

Commentary: Treatment Failure and Success: A Commentary on Defining and Treating Pediatric Treatment-Resistant Depression - Reflections on Dwyer Et Al. (2020)

Jeffrey R Strawn et al. J Child Psychol Psychiatry.

Abstract

Nearly two in five youth with major depressive disorder fail to respond to first-line interventions. As such, treatment-resistant depression represents a formidable challenge for clinicians and researchers. In fact, even considering the diagnosis of treatment-resistant depression in children and adolescents requires (a) defining treatment-resistant depression and, by extension, treatment failure; (b) defining recovery; (c) understanding its developmental trajectory; and in addition to (d) understanding the evidence for treatment interventions in this population. Accumulating data suggest that treatment-resistant depression is heterogeneous and that this heterogeneity may inform interventions. Additionally, these data suggest that substantially more nuance is needed in evaluating the 'adequacy' of prior treatments whether they are psychotherapeutic or psychopharmacologic. Last, adjunctive interventions that focus on neuromodulation, glutamatergic, GABAergic, and inflammatory pathways remain poorly understood in youth with treatment-resistant depression despite very significant advances in adults with treatment-resistant depression.

Keywords: Depression; major depressive disorder; treatment-resistant depression.

Similar articles

See all similar articles

References

    1. Brent, D., Emslie, G., Clarke, G., Wagner, K.D., Asarnow, J.R., Keller, M., … & Zelazny, J. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA, 299, 901-913.
    1. Curry, J., Rohde, P., Simons, A., Silva, S., Vitiello, B., Kratochvil, C., … & March, J. (2006). Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1427-39.
    1. Dwyer, J.B., Stringaris, A., Brent, D.A., & Bloch, M.H. (2020). Annual Research Review: Defining and treating pediatric treatment-resistant depression. Journal of Child Psychology and Psychiatry, 61, 312-332.
    1. Forbes, E.E., Stepp, S.D., Dahl, R.E., Ryan, N.D., Whalen, D., Axelson, D.A., … & Silk, J.S. (2012). Real-world affect and social context as predictors of treatment response in child and adolescent depression and anxiety: An ecological momentary assessment study. Journal of Child and Adolescent Psychopharmacology, 22, 37-47.
    1. Ramsey, L.B., Bishop, J.R., & Strawn, J.R. (2019). Pharmacogenetics of treating pediatric anxiety and depression. Pharmacogenomics, 20, 867-870.

LinkOut - more resources

Feedback